Mild Cognitive Impairment Clinical Trial
Official title:
The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.
Verified date | August 2017 |
Source | Tufts University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cognitive impairment is also a major risk factor for development of dementia later in life.
Findings from our studies suggest that the carotenoids, lutein and zeaxanthin may be
important in cognitive function in the elderly. The investigators have previously reported
eggs to be a highly bioavailable source of lutein and zeaxanthin. Our study evaluates
long-term egg intervention as a treatment strategy for age-related cognitive impairment which
could possibly prevent the onset of dementia. The investigators have also shown that lutein
supplementation significantly improved verbal fluency scores in healthy older women. Our
studies have shown that egg interventions can significantly increase serum lutein
concentrations in older adults. Based on the sum of our findings, the next logical step will
be to investigate the ability of lutein and zeaxanthin contained in eggs to influence
cognitive function in older adults. The investigators hypothesize that there will be a
significant increase in cognitive function measures in older adults provided with meals
containing 2 egg/day at the end of 6 months, while no significant improvements will be
observed in older adults given daily meals containing egg substitute.
The proposed study is designed as a randomized, placebo controlled trial that tests the
effects of 6 month supplementation with 2 eggs/day on cognitive function in older adults.
Secondary analyses will determine whether baseline MP density predicts relative effectiveness
of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of
oxidative stress and inflammation.
Status | Completed |
Enrollment | 44 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - men and women age > 50 years - BMI 19-30 kg/m2 - lutein intake of < 3 mg/d - DHA (docosahexaehoic acid) intake < 250 mg/d (including supplements) - Mini mental state exam (MMSE) score > 24 (Appendix B) - macular pigment density < 0.5 at 0.5 degrees - Beck Depression Inventory < 20 - free of known disease; - BMI 19-29 kg/m2 - must be able to give written informed consent - have normal hematologic parameters - normal values of plasma albumin - normal values for liver and kidney function (Appendix A) - no use of carotenoid, n3 fatty acid, multivitamin/mineral, or choline supplements (> 3 months). |
Country | Name | City | State |
---|---|---|---|
United States | Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Tufts University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | cognition | measures of attention, executive function, verbal fluency will be made using a sensitive computerized program | 6 months | |
Secondary | inflammation | markers of inflammation will be made in plasma | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |